These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 8354928)
21. Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses. Celebi G; Baruönü F; Ayoğlu F; Cinar F; Karadenizli A; Uğur MB; Gedikoğlu S Jpn J Infect Dis; 2006 Aug; 59(4):229-34. PubMed ID: 16936340 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Green M; Choules G; Rogers D; Titball RW Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452 [TBL] [Abstract][Full Text] [Related]
23. [Streptococcus pneumonia infection and positive blood culture with Francisella tularensis, in a renal transplant recipient]. Faucon AL; Zamfir O; Dupouët L; Pruna A Presse Med; 2011 Dec; 40(12 Pt 1):1199-202. PubMed ID: 21816564 [No Abstract] [Full Text] [Related]
25. Pneumonic tularemia presenting with a vesicular eruption. Marquart JD; Clifford R Cutis; 2015 Apr; 95(4):E17-8. PubMed ID: 25942033 [No Abstract] [Full Text] [Related]
26. Glycogen synthase kinase-3beta (GSK3beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Zhang P; Katz J; Michalek SM Mol Immunol; 2009 Feb; 46(4):677-87. PubMed ID: 18929413 [TBL] [Abstract][Full Text] [Related]
27. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge. Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555 [TBL] [Abstract][Full Text] [Related]
28. A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia. Hall CA; Flick-Smith HC; Harding SV; Atkins HS; Titball RW Antimicrob Agents Chemother; 2016 Dec; 60(12):7206-7215. PubMed ID: 27671061 [TBL] [Abstract][Full Text] [Related]
29. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834 [TBL] [Abstract][Full Text] [Related]
30. Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice. Lee BY; Li Z; Clemens DL; Dillon BJ; Hwang AA; Zink JI; Horwitz MA Small; 2016 Jul; 12(27):3690-702. PubMed ID: 27246117 [TBL] [Abstract][Full Text] [Related]
31. Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections. Das D; Chen J; Srinivasan S; Kelly AM; Lee B; Son HN; Radella F; West TE; Ratner DM; Convertine AJ; Skerrett SJ; Stayton PS Mol Pharm; 2017 Jun; 14(6):1988-1997. PubMed ID: 28394614 [TBL] [Abstract][Full Text] [Related]
33. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Mason WL; Eigelsbach HT; Little SF; Bates JH Am Rev Respir Dis; 1980 Jan; 121(1):39-45. PubMed ID: 7352712 [TBL] [Abstract][Full Text] [Related]
34. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Quarry JE; Isherwood KE; Michell SL; Diaper H; Titball RW; Oyston PC Vaccine; 2007 Mar; 25(11):2011-8. PubMed ID: 17241711 [TBL] [Abstract][Full Text] [Related]
35. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Twine S; Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W Vaccine; 2012 May; 30(24):3634-45. PubMed ID: 22484348 [TBL] [Abstract][Full Text] [Related]
36. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis. Shen H; Chen W; Conlan JW Microb Pathog; 2004 Aug; 37(2):107-10. PubMed ID: 15312850 [TBL] [Abstract][Full Text] [Related]
37. Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B. Fritz DL; England MJ; Miller L; Waag DM Comp Med; 2014 Oct; 64(5):341-50. PubMed ID: 25402174 [TBL] [Abstract][Full Text] [Related]
38. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754 [TBL] [Abstract][Full Text] [Related]
39. Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting. Naughton M; Brown R; Adkins D; DiPersio J Bone Marrow Transplant; 1999 Jul; 24(2):197-9. PubMed ID: 10455349 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model. Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]